| http://www.w3.org/ns/prov#value | - Insurers, patients and other payers are pushing back against what they believes is the exorbitant fee that Gilead (GILD) is charging for its new hepatitis C drug Sovaldi.Previously: Pfizer lung-cancer drug fails in two Phase III studies The pill costs $1,000 a pop, or $84,000 for a 12-week treatment vs $66,000 for the current standard of care.The likes of Express Scripts (ESRX), Catamaran (CTRX),
|
